Document is current
Any future updates will be listed below
-
Authors
Antill, Yoland https://orcid.org/0000-0002-6366-5523
Kok, Peey-Sei
Robledo, Kristy
Yip, Sonia
Cummins, Michelle
Smith, Deborah
Spurdle, Amanda
Barnes, Elizabeth
Lee, Yeh Chen
Friedlander, Michael
Baron-Hay, Sally
Shannon, Catherine
Coward, Jermaine
Beale, Philip
Goss, Geraldine
Meniawy, Tarek
Lombard, Janine
Andrews, John
Stockler, Martin R
Mileshkin, Linda
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03015129 at ClinicalTrials.govDocuments that mention this clinical trial
Endometrial carcinosarcoma
https://doi.org/10.1136/ijgc-2022-004073
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
https://doi.org/10.1136/jitc-2020-002255
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
